## **1 DNA Methylation Predicts Adverse Outcomes of Coronary**

## 2 Artery Disease

3

Min Qin<sup>1,2,3,8</sup>, Qili Wu<sup>1,2</sup>, Xiaoxue Tian<sup>1,2</sup>, Qian Zhu<sup>1,2</sup>, Xianhong Fang<sup>4</sup>, Xiaoping
Chen<sup>5</sup>, Chen Liu<sup>6</sup>, Bin Zhang<sup>4</sup>, Hanping Li<sup>2</sup>, Xipei Wang<sup>7</sup>, Cuiping Pan<sup>8,9#</sup>, Shilong
Zhong<sup>1,2,3,7#</sup>

- 7
- 8 Affiliations:
- 9 1. Department of Pharmacy, Guangdong Provincial People's Hospital (Guangdong
  10 Academy of Medical Sciences), Southern Medical University, Guangzhou, China
- Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention,
   Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital
   (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou,
   China

15 3. School of Medicine, South China University of Technology, Guangzhou, China

- Department of Cardiology, Guangdong Provincial Key Laboratory of Coronary Heart
   Disease Prevention, Guangdong Cardiovascular Institute, Guangdong Provincial
   People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical
   University, Guangzhou, China
- 20 5. Department of Clinical Pharmacology, Xiangya Hospital, Central South University,
  21 Changsha, 410008, Hunan, China.
- Department of Cardiology, The First Affiliated Hospital of Sun Yat-Sen University,
   Guangzhou, 510080, Guangdong, China.
- Laboratory of Phase I Clinical Trials, Medical Research Center of Guangdong
   Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern
   Medical University, Guangzhou, China

- 1 8. Center for Intelligent Medicine Research, Greater Bay Area Institute of Precision
- 2 Medicine (Guangzhou), School of Life Sciences, Fudan University, Guangzhou, China
- 3 9. Center for Evolutionary Biology, Fudan University, Shanghai, China.
- 4 # Correspondence
- 5 Cuiping Pan: pancuiping@ipm-gba.org.cn
- 6 Shilong Zhong: gdph\_zhongsl@gd.gov.cn and zhongsl@hotmail.com
- 7
- 8
- 9

# 1 Table of Contents

2	Abstract	4
3	Introduction	5
4	Methods	6
5	Cohort assembly and baseline information collection	6
6	DNA extraction from blood leukocytes	7
7	Genome-wide DNA methylation profiling and data preprocessing	
8	Epigenome-wide association analysis	9
9	Characterizing genomic locations of DMPs	10
10	Target gene predictions	10
11	Construction of prognostic models for death and MACE	
12	Pleiotropic association analysis of DMPs and eQTL	
13	Genome-wide association study of death and MACE	
14	Differential gene expression analysis in MI and stroke	
15	Statistical tests	14
16	Results	14
17	Baseline characteristics of the study population	
18	EWAS identified differentially methylated CpGs for death and MACE	
19	Pathways and mediating phenotypes of DMPs	17
20	Prognostic models for death and MACE in CAD	19
21	Contribution of genetic regulation to CAD prognosis	21
22	Prognostic genes in acute MI and stroke	23
23	Discussion	25
24	Acknowledgements	
25	Funding	
26	Conflict of interest	
27	Data availability	
28	Code availability Error! Bookmark n	ot defined.
29	Author Contributions	
30	Ethical approval	31
31	References	31
32	Figure Legends	
33		

34

# 1 Abstract

## 2 Background

Adverse outcomes including myocardial infarction and stroke render coronary artery
disease (CAD) a leading cause of death worldwide. Biomarkers that predict such
adversity enable closer medical supervision and opportunities for improved outcomes.

#### 6 **Methods and results**

7 We present a study of genome-wide DNA methylation profiling in 933 CAD patients 8 with up to 13 years of clinical follow-up. We discovered 115 methylation sites 9 associated with poor prognosis and inferred that cellular senescence, inflammation, 10 and high-density lipoprotein mediated the adversity. We built succinct prognostic 11 models combining a few methylation sites and clinical features, which could stratify 12 patients of different risks. Furthermore, we assessed genetic regulation of the 13 differential methylation by interrogating QTL effects. Prognostic genes such as 14 FKBP5, UBE2E2 and AUTS2 appeared recurrently in various analyses and were 15 validated in patients of myocardial infarction and stroke.

## 16 Conclusions

17 Our study provides prognostic models for clinical application and revealed18 methylation biomarkers and mechanisms of CAD adverse outcomes.

## 19 Key words:

20 coronary artery disease; prognostic model; machine learning; DNA methylation;
21 inflammation; death;

22

4

# 1 Introduction

2 Coronary artery disease (CAD) is life-threatening and represents a universal leading cause of death <sup>1-3</sup>. Studies of the last century suggested a 15-year survival rate of 48-3 70%<sup>4,5</sup>. Despite the remarkable amelioration in the recent 30 years in managing its 4 5 clinical risk factors and the secondary and tertiary preventions, CAD is associated with 17.8 million annual deaths worldwide <sup>6,7</sup>. Identifying patients with greater risk of 6 7 poor prognosis enables closer medical supervision and therefore opportunities for 8 better clinical outcomes. Numerous genetics-based research reported novel targets 9 and tools for predicting adverse outcomes in CAD patients. Indeed, CAD has an estimated heritability of 0.38-0.66 for incidence <sup>8</sup> and 0.38-0.57 for mortality <sup>9</sup>. 10 11 However, towards which direction it progresses is multifactorial determined by the 12 combined effects of genetic and environmental factors, therefore we reason that 13 considering multiple layers of information, such as genetics and epigenetics, will 14 better identify patients susceptible to poor prognostic outcomes.

15 DNA methylation on CpG (cytosine-phosphate-guanine) dinucleotides, a 16 stable yet dynamic regulation mechanism reflecting both genetics and environment, 17 enables exploring their integrated effects on diseases. Epigenome-wide association 18 studies (EWAS) suggested DNA methylation as a feasible biomarker for CAD. Two 19 recent large-scale EWAS surveyed multiple cohorts of various ancestries and 20 collectively reported 85 DNA methylation sites in blood leukocytes to be associated with incident CAD or myocardial infarction (MI)<sup>10,11</sup>. Comprehensive studies also 21 22 report association between DNA methylation and the risk factors of CAD including aging <sup>12</sup>, smoking <sup>13</sup>, blood lipids <sup>14</sup>, inflammation <sup>15</sup>, hypertension <sup>16</sup>, and diabetes 23 mellitus (DM)<sup>17</sup>. Furthermore, initial EWAS studies identified strong signals that 24

predicted all-cause death of cardiovascular diseases <sup>18,19</sup>, albeit its biological
 mechanisms remained to be explored. As such, DNA methylation indicates not only
 the risk of CAD incidence but also its progression.

4 In this study, we conducted a two-stage multicenter EWAS on prognosis of 5 CAD in 933 patients, profiling blood leukocyte-derived DNA methylation by Illumina 6 MethylationEPIC BeadChip and interrogating its association with patient outcomes in 7 up to 13 years of follow-up. We defined the primary endpoint as all-cause death and 8 the secondary endpoint as major adverse cardiovascular events (MACE), including 9 death, nonfatal myocardial infarction, coronary revascularization, and stroke. From 10 differentially methylated probes/sites (DMPs), we inferred mediating phenotypes, 11 built risk prediction models, assessed the contribution of genetic regulation, and 12 finally, evaluated how the genes impacted by DMPs were expressed during the 13 adverse events. Our results show that DNA methylation of leukocytes from peripheral 14 blood provides robust biomarkers and rich insights into the prognosis of CAD.

## 15 Methods

### 16 Cohort assembly and baseline information collection

17 This study was approved by the Medical Research Ethics Committee of 18 Guangdong Provincial People's Hospital (approval number: GDREC2017071H) and 19 complied with the Declaration of Helsinki. All patients provided written informed 20 consents.

We recruited over 5,000 CAD patients from three medical centers in two areas
 of China for studying the prognosis of CAD, namely Guangdong Provincial People's
 Hospital, First Affiliated Hospital of Sun Yat-sen University, and Xiangya Hospital of

Central South University<sup>20</sup>. We selected 405 patients recruited between January 2010 1 2 to December 2017 from Guangdong Provincial People's Hospital to form the 3 discovery cohort, based on a nested case-control study design. 528 patients recruited 4 from 2017 to 2018 from all three medical centers were assembled as the validation 5 cohort. All cohort participants were identified either with a history of coronary artery 6 bypass graft operation or newly diagnosed by coronary angiography and carotid artery 7 ultrasonography to have  $\geq$ 50% obstruction, as assessed by the luminal diameter, in 8 minimally one main coronary artery. The inclusion criteria were: (1) aged over 30 9 years old, (2) no history of renal transplantation or dialysis, (3) no cirrhosis, (4) not 10 pregnant nor breastfeeding, (5) no malignancy, (6) no history of haemodialysis; (7) no 11 history of thyroid problems, not using antithyroid drugs nor thyroid hormone 12 medication in the past week, and (8) completed the follow-up surveys.

13 The cohort participants were admitted to hospitals; after overnight fasting, their blood 14 samples were drawn at 7AM on the second morning. Clinical laboratory tests were 15 performed and detailed clinical surveys, including medical history, family history, 16 smoking status, and medication intake were collected as baseline information. 17 Echocardiography was used to determine the function and structure of the left 18 ventricle (LV). All patients were followed up by telephone every six months by the 19 medical staff team for inquiring about occurrences of all-cause death or major adverse 20 cardiovascular events (MACE), with the latter defined as nonfatal myocardial 21 infarction, coronary revascularization, stroke, and death.

### 22 DNA extraction from blood leukocytes

Whole blood was collected in EDTA-K2 anticoagulant tubes and immediately
separated into plasma and hemocyte by centrifuging at 1000 g for 10 min at 4°C.

- 1 Genomic DNA was extracted from hemocyte and transferred to cryopreservation
- 2 tubes, which were stored at  $-80^{\circ}$ C for subsequent experiments.

#### **3** Genome-wide DNA methylation profiling and data preprocessing

4 DNA quality was assessed by ultraviolet spectrophotometer (Thermo Scientific, 5 NanoDrop 2000). Briefly, about 500 ng of DNA was treated with sodium bisulfite for 6 converting unmethylated nucleotide C to U, using the EZ DNA Methylation Kit 7 (Zymo Research). After the conversion, methylation levels of more than 850,000 CpG 8 sites were quantified using the Illumina Infinium MethylationEPIC BeadChip, which 9 was run on an Illumina iScan Systems according to the manufacturer's standard 10 protocol. DNA methylation profiling was serviced by Genenergy Inc. The 11 experimental operator was blind to the group information and randomly assigned the 12 samples to different chips and plates.

13 Raw signal intensities of DNA methylation were stored in .idat files and imported to the R environment using the "ChAMP" package <sup>21,22</sup>. Analysis was performed 14 15 separately for the discovery cohort and the validation cohort. Methylation level of 16 each probe, i.e., beta value, was defined as Meth/(Meth + Unmeth + 100), where 17 Meth was signal intensity of the CpG site in methylated form and Unmeth was that in 18 unmethylated form. Beta values ranged from 0 to 1, with a larger value indicating a 19 higher level of methylation. Probes were excluded if meeting one of the following 20 criteria: (1) with detection P value  $\geq 0.01$ , (2) with beadcount <3 in at least 5% of 21 samples, (3) DNA methylation occurring to non-CpG dinucleotides, (4) aligning to multiple locations<sup>23</sup>, (5) located on chromosome X or Y. In total, 733,638 probes in 22 23 the discovery cohort and 738,366 probes in the validation cohort were retained.

The qualified probes were normalized with the BMIQ method <sup>24</sup> to correct for signal 1 2 bias caused by type-I and type-II probes on the array. Next, we used the method proposed by Houseman et al.<sup>25</sup> to estimate the relative proportions of blood cells, 3 4 including CD8 lymphocytes, CD4 lymphocytes, natural killer cells, B cells, 5 monocytes, and granulocytes. We also leveraged 224 positive control probes to 6 evaluate the impact of technical confounders, which we generally referred as batch 7 effect, on the DNA methylation values. Briefly, we computed the principal 8 components (PCs) of these positive control probes and assessed the association 9 between the first 20 PCs and several technical parameters, including the indices for 10 bisulfite conversion batch, plates, sample wells and chip. Methylation residuals were 11 then obtained via linear regression, with the beta value of each probe as independent 12 variable, and age, sex, smoking status, estimated white-blood-cell proportions, and the 13 top 10 PCs of positive control probes as dependent variables.

### 14 Epigenome-wide association analysis

15 Cox regression-based survival analysis was employed to explore the association 16 between each methylation residual and the trait, i.e., all-cause death or MACE. We 17 performed such EWAS separately for the discovery and the validation cohorts. In 18 each EWAS, we adjusted for age, sex, smoking status, percutaneous coronary 19 intervention (PCI), arrhythmia, heart failure, hypertension, hyperlipidemia, and 20 medication intake including  $\beta$ -receptor blocker (BB), angiotensin converting enzyme 21 inhibitors (ACEI), calcium channel blocker (CCB), proton pump inhibitor (PPI), 22 clopidogrel, and aspirin. A strict epigenome-wide significance threshold by 23 Bonferroni correction was set as P < 6.83E-08 and a moderate threshold by Benjamini 24 & Hochberg correction was set as FDR < 0.05. The differentially methylated site was 25 considered validated when the association showed a consistent direction of effect in 1 both cohorts, with *FDR* < 0.05 in the discovery cohort and P < 0.05 in the validation

2 cohort.

#### **3** Characterizing genomic locations of DMPs

Genomic locations of DMPs were annotated by Annovar<sup>26</sup>. Overlap with regulatory 4 5 elements were computed based on ENCODE Encyclopedia version 5 (ENCODE5) cCRE catalog<sup>27</sup>, including insulators, promoters, distal enhancers, and proximal 6 7 enhancers. Enrichment against tissue- and cell type- specific regulatory elements was 8 performed based on histone modification chromatin immunoprecipitation peaks (ChIP) 9 (H3K4me1, H3K4me3, H3K27me3, H3K36me3, H3K9me3, and H3K27ac marks) 10 and regions of 15 chromatin states across 299 cell types and tissues from Roadmap Epigenomics <sup>28,29</sup> in eFORGE v2.0 (https://eforge.altiusinstitute.org/). 11

#### 12 Target gene predictions

13 We predicted the target genes impacted by the DMPs by two methods. For one, we 14 used the annotation file provided by Illumina, which assigned each CpG site to its 15 nearest gene. For the other, we leveraged the activity-by-contact (ABC) model developed by Nasser et al. <sup>30,31</sup>, which identified active enhancers in a particular cell 16 17 type and predicted their target genes based on chromatin states and three-dimensional 18 contacts. To identify the ABC enhancers that overlap with DMPs, we adopted the GWAS annotation approach by Zhang K et al.  $^{32}$  by adding ±2500 bp to the genomic 19 20 location of DMPs and overlapped them with the ABC enhancers of 131 human cell 21 types. We adopted the original ABC score thresholds, namely  $\geq 0.015$  for distal 22 element-gene connections and  $\geq 0.1$  for proximal promoter-gene connections, to 23 define DMP – enhancer – target gene connections.

#### 1 Construction of prognostic models for death and MACE

2 Risk prediction models were constructed based on the discovery cohort and tested in 3 the validation cohort. For building the methylation model of death, 21 DMPs passing 4 the Bonferroni-corrected epigenome-wide significance threshold were pruned by a 5 random forest approach (feature pruning) and those retained were fit by the 6 multivariate Cox regression to derive the final model (weight tuning). For feature 7 pruning, the parameters  $m_{try}$  and  $n_{tree}$  in the random forest models were tuned using 8 the out of bag error for deriving a minimal overall misclassification rate.  $m_{try}$  refers to 9 the number of variables tried at each split and  $n_{tree}$  refers to the number of trees to be 10 grown in a forest. The top 10 DMPs with the largest variable importance measure 11 (VIM), which denoted the contribution of each input feature to the model, were 12 retained. For the risk model of MACE, all eight DMPs passing the Bonferroni-13 corrected epigenome-wide significance threshold were retained. In weight tuning, the 14 retained DMPs were fit by multivariate Cox regression in the R package "survival". 15 For deriving robust AUC (The area under the receiver operating characteristic (ROC) 16 curve) values, we adopted a process of 80:20 data split and 1,000 times cross 17 validation. The final model was obtained by combining all patients in the discovery 18 cohort.

We applied two types of models to the multi-center validation cohort for testing their performances, with one combining CpG sites, sex, and age, and the other combining CpG sites, sex, age, HDLC, Fibrinogen, and LVEF. Prediction risk scores for fiveyear survival were computed, and Wilcoxon test was used to assess whether the scores between the two groups of patients, i.e., with and without the events of death or MACE, were significantly different. The sensitivity and specificity of these two

11

models were computed using the ConfusionMatrix function from the R package
 "caret".

Several clinical features were also assessed for their capability in predicting CAD
prognostic outcomes, alone or in combination with other clinical features and the
selected methylation sites, using the R package "survival".

#### 6 Pleiotropic association analysis of DMPs and eQTL

Summary-data based Mendelian Randomization (SMR) analysis <sup>33</sup> and the 7 8 Heterogeneity in Dependent Instruments (HEIDI) test were employed to identify 9 pleiotropic relationships between the **DMPs** and gene expression 10 (https://yanglab.westlake.edu.cn/software/smr/#Download). GWAS summary 11 statistics for DNA methylation in Asian populations, and therefore information of methylation quantitative trait loci (meQTL), were obtained from Peng et al <sup>34</sup>. The 12 13 association strength *beta* theoretically ranges between -1 and 1 for maximally 14 negative to maximally positive associations. The information of cis-eQTL were 15 downloaded from eQTLGen (https://www.eqtlgen.org/). Allele frequencies were 16 obtained by referring to the East Asians in the 1000 Genomes Project reference panel (phase3, version5)  $^{35}$ . 69 DMPs with at least one *cis*-meOTL (P <1.0E-08) were 17 18 selected for computing causal relationships with *cis*-regulated gene expression. The 19 CpG-gene expression associations with a Bonferroni-corrected P value (P < 0.05/69 =20 7.25E-04) were further selected for the HEIDI test ( $P_{\text{HEIDI}} > 0.05$ ) to distinguish 21 pleiotropy from linkage.

#### 1 Genome-wide association study of death and MACE

2 We performed genome-wide association studies (GWAS) on death and MACE in 3 1,551 CAD patients recruited from Guangdong Provincial People's Hospital, Xiangya 4 Hospital of Central South University, and the First Affiliated Hospital of Sun Yat-sen 5 University. These patients were genotyped by Illumina Infinium GSA-24 v1.0 bead 6 chip on 700,078 single-nucleotide genomic positions, which, after genotype 7 imputation against the East Asian populations in the 1000 Genomes Project, 8 generated 3,435,397 high-quality single nucleotide variants (SNVs). Details about 9 cohort enrollment, baseline characteristics, data quality control, and genotype imputation were described previously <sup>20</sup>. Logistic regression was employed for the 10 11 GWAS via the PLINK software (version 2.0). The first 10 principal components, sex, 12 age, smoking status, percutaneous coronary intervention (PCI), arrhythmia, heart 13 failure, hypertension, hyperlipidemia, and medication intake including  $\beta$ -receptor 14 blocker (BB), angiotensin converting enzyme inhibitors (ACEI), calcium channel 15 blocker (CCB), proton pump inhibitor (PPI), clopidogrel, and aspirin were included as 16 covariates.

## 17 Differential gene expression analysis in MI and stroke

We obtained from Kuppe et al <sup>36</sup> single-nucleus RNA sequencing data from 19 patients with acute MI and four non-transplanted heart donors as controls. A total of 191,795 nuclei from 31 tissue samples, including ten major cardiac cell types, were obtained. We performed differential gene expression analysis between the MI patients and controls, as well as among three tissue zones, namely myogenic, ischemic, and fibrotic zones. We also assessed differences between groups by cell types. Wilcoxon tests implemented in the FindMarkers function of the R package "Seurat" were used

1  $^{37}$ . Genes passing the Bonferroni-corrected *P* value of 0.05 were considered 2 differentially expressed. Time-series expression analysis based on Fuzzy C-means 3 clustering was used to demonstrate the relative expression changes of prognostic 4 genes.

5 We obtained bulk RNA sequencing of peripheral blood from patients of MI <sup>38</sup> and 6 patients of ischemic stroke <sup>39</sup>. Differential gene expression analysis was performed 7 between patients and controls using the R package "limma" <sup>40</sup>.

#### 8 Statistical tests

9 Baseline demographic and clinical characteristics were presented as mean  $\pm$  standard 10 deviation for continuous variables and counts (%) for categorical variables. Cox 11 regression-based survival analysis was employed for assessing association between 12 the features and outcomes. Linear regression was used to explore the relationships 13 between DMPs and six inflammatory markers, four blood lipids and two left 14 ventricular indices. Enrichment analysis of biological pathways and traits in GWAS 15 Catalogue database were carried out by R package "enrichR" and terms with a P 16 value smaller than 0.05 was considered as significant. Unless stated, P values derived 17 from multiple tests were corrected by methods of FDR or Bonferroni correction. 18 Wilcoxon test was used to assess if the difference of continuous variables between 19 two groups were statistically significance. For counts, chi-square tests were used.

# 20 **Results**

#### 21 **Baseline characteristics of the study population**

We adopted a two-stage multicenter design for studying DNA methylation related to CAD prognosis (*Figure 1a*). We assembled over 5,000 CAD patients from a

large medical center in China and based on the nested case-control study design, selected 405 patients to form the discovery cohort. As such, a total of 217 deaths and 247 MACE events were recorded in up to 13 years of follow-up, while 158 patients experienced no adversity. For the validation cohort, we chose a forward study design and enrolled 528 CAD patients from three medical centers in China. We followed the patients in the validation cohort for about 3 years and observed 25 deaths and 41 MACE events.

8 The baseline characteristics of the patients at the time of enrollment were 9 expounded in Supplementary data online, Table S1 and Figure S1. Consistent with 10 epidemiological observations, our CAD patients were mainly men aged over 60 years 11 (73%). We documented their basic demographic information, medical history, 12 biomedical measurements after overnight fasting, and medication intake during the 13 ascertained periods. The measurements were comparable between the two cohorts (P >14 (0.05), except for a few, most of which were included as covariates in our statistical 15 tests. Overall, the two cohorts displayed similar patient characteristics. The follow-up 16 times and event times are displayed in Supplementary data online, Figure S1.

#### 17 EWAS identified differentially methylated CpGs for death and MACE

We extracted DNA from leukocytes in peripheral blood and performed genome-wide methylation profiling via the Illumina Infinium MethylationEPIC BeadChip. After stringent quality control (see Supplementary data online, *Figure S2*), we obtained 733,737 and 738,021 high-quality CpG probes from the discovery and the validation cohorts, respectively.

Next, we employed Cox regression for EWAS on the high-quality DNA
 methylation sites against the survival of all-cause death or MACE (see Supplementary

1 data online, Figure S3a-S3b and Table S2-S4). In the discovery cohort, after 2 correcting for sex, age, smoking status, percutaneous coronary intervention, heart 3 failure, hypertension, arrhythmia, hyperlipidemia, and medications, a total of 554 4 differentially methylated CpGs (DMPs) passed the moderate significance threshold 5 (FDR adjusted P, i.e., Q < 0.05, Figure 1b). In the validation cohort, 105 of the 554 6 DMPs were replicated, defined by P < 0.05 and consistent direction of effect. 7 Remarkably, 21 DMPs in the discovery cohort remained significant after the epigenome-wide Bonferroni correction (P < 6.83E-08), and six of them were 8 9 replicated in the validation cohort (P < 0.05). Similarly, we performed EWAS on the 10 secondary endpoint, MACE. 30 out of the 95 DMPs were validated, among which 11 five passed the Bonferroni-corrected threshold.

12 Overall, 115 DMPs were detected in both cohorts as associated with adverse 13 outcomes of CAD, with most showing increased methylation (Figure 2a, 14 Supplementary data online, Figure S3 and Table S5). Notably, 60% DMPs were reported in EWAS Catalog<sup>41</sup> and EWAS Atlas<sup>42</sup> to connect to a variety of traits and 15 diseases, including Crohn's disease and inflammatory bowel disease (25 DMPs), 16 smoking (16 DMPs), aging (8 DMPs), and C-reactive proteins (6 DMPs)<sup>15</sup>. 17 Associations with body mass index <sup>17,43</sup>, atherosclerotic plaque <sup>44</sup>, and death risk <sup>45</sup> 18 19 were also observed.

These 115 DMPs tend to reside in non-coding regions, particularly distal enhancers (see Supplementary data online, *Figure S4a-S4b*). Overlap with histone modification ChIP peaks and the 15 chromatin states from Roadmap (**Methods**) revealed that these DMPs were strongly enriched in enhancers specific to blood monocytes, adipocytes, myoepithelial cells, and fibroblasts. Furthermore, the left ventricle and right atrium also appeared on the top of the list (Q < 0.05, see

1 Supplementary data online, *Figure S4c-S4d*). These results suggest that the DMPs 2 were prone to occur in regions characteristic of heart traits. Note that our DNA 3 methylation were derived from blood leukocytes; however, the DMPs tend to locate 4 in enhancers characteristic of not only blood but also tissues and cells of non-blood 5 origin yet known to play critical roles in CAD. Given that both DNA methylation and RNA transcription in blood were distinct from solid organs <sup>46</sup>, our observation 6 7 suggested that methylation in leukocytes indeed carried pathophysiological features 8 and therefore suitable to serve as biomarkers

9 A main function of methylation is to regulate gene expression. By annotating 10 DMPs to the closest genes, we discovered 100 prognostic genes, which were highly 11 enriched for apoptotic pathways, stress response, inflammation response, and vascular 12 processes (*Figure 2b*). Furthermore, these genes were enriched for CAD and immune 13 traits as recorded in the GWAS Catalog (*Figure 2c*).

## 14 Pathways and mediating phenotypes of DMPs

15 We also interrogated target genes by querying the connections of enhancers to 16 target genes via the Activity-by-Contact (ABC) model, which leveraged chromatin 17 states and three-dimensional contacts (Methods). For linking DMPs to enhancers, we 18 adopted a liberal approach in Boix et al. (Methods) for connecting GWAS loci to 19 enhancers, by which we extended the DMPs by adding 2500 bp to both flanking 20 regions. Next, we assessed if the 5 Kb regions overlapped with any enhancers, which 21 in turn were connected to genes via the ABC model. In this way, 83 of the 115 DMPs 22 (72.1%) were connected to 806 genes (see Supplementary data online, *Table S6*). 23 Consistent with the closest gene annotation, these genes were enriched for 24 inflammation and cellular senescence (P < 0.05). Notably, three methylation sites, 25 cg25114611, cg25500196, and cg25563198, were each predicted to interact with > 50

genes. These big gene clusters were strongly enriched in stress-induced senescence and inflammation response (Q < 0.05) (see Supplementary data online, *Figure S5*). Furthermore, all three DMPs were located on super-enhancers active in CAD relevant tissues, such as blood, lymphoid, adipose tissue, heart ventricle, and aorta<sup>47</sup>.

5 Theoretically, the ABC target genes entail cell type-specific functions, due to 6 enhancers' selective activity in different cells. Among the blood cells, the target genes 7 displayed an enrichment for JAK-STAT and interleukin (IL) pathways (IL-2, IL-7, 8 IL-9, and IL-15) in monocytes and T helper cells, whereas an enrichment for IL-17 9 pathway was found active in more diverse cell types, including monocytes, 10 macrophages, CD4+ T helper cells, and CD19+ B cells (see Supplementary data 11 online, *Table S7*). We also extended the analysis to all 131 human cell types and 12 tissues in the ABC model and found these immune pathways active in 24% of the 13 tissues and cell, including those closely related to CAD, e.g., coronary artery, adipose, 14 liver, epithelium, and T cells (see Supplementary data online, *Figure S6*), suggesting 15 the adverse outcomes involved robust immune response pathways. There also 16 appeared to be a marginal enrichment of lipid response in T cells and mitochondrial 17 processes in monocytes and dendritic cells (P < 0.05).

18 We verified the connection of the DMPs to inflammation and lipids in clinical 19 measurements (see *Figure 2d* and Supplementary data online, *Table S8*). In both the 20 discovery and the validation cohorts and out of the 115 DMPs, 43 DMPs displayed 21 association with systemic immune-inflammation index (SII) as defined by neutrophil 22 count  $\times$  platelet count / lymphocyte count <sup>48</sup>, 37 DMPs associated with a chronic lowgrade inflammation index *fibrinogen*<sup>49</sup>, and 15 DMPs associated with a marker for 23 acute inflammation prothrombotic status *platelet-lymphocyte ratio* (PLR)<sup>50</sup>. Several 24 25 other inflammation markers were also investigated; however, the associations were

1 comparably weaker and non-consistent. For lipids, a strong connection of 29 DMPs to 2 high-density lipoprotein cholesterol (HDLC) was observed. Interestingly, few 3 connections were found for low-density lipoprotein cholesterol (LDLC), total 4 cholesterol, or triglycerides (TG). We also examined left ventricular ejection fraction 5 (LVEF) and left ventricular mass index (LVMI), as low LVEF and high LVMI were 6 indicative of LV remodeling and therefore increased risk of death or MACE in CAD. 7 25 and 15 DMPs were respectively associated with LVEF and LVMI, and 8 reassuringly, most of these associations displayed opposite directions for both traits.

#### 9 **Prognostic models for death and MACE in CAD**

10 Risk prediction models help to identify CAD patients with greater risk of developing 11 adverse outcomes. We constructed models based on DMPs that displayed epigenome-12 wide significance of association in the discovery cohort (n=405). We leveraged a 13 random forest approach to select DMPs that contributed the most to the classification 14 accuracy, and derived precise weights by the multivariable Cox regression-based 15 survival analysis (Methods, see Supplementary data online, Figure S7). As such, we 16 constructed prognostic models for death with 10 CpGs and for MACE with 8 CpGs, 17 which we termed the CG prognostic models (*Table 1*). This model for death achieved 18 an area under the curve (AUC) of 0.70 in the discovery cohort, close to or better than 19 using traditional risk factors including sex (AUC = 0.52), chronological age (AUC = 20 (0.72) and their combination (AUC = 0.72). Combining sex, chronological age, and 21 the 10 CpGs improved the prediction power (AUC = 0.80) (*Figure 3a*). We also built 22 prognostic models based on the mediating phenotypes. Although not all the clinical 23 features were equally powerful in predicting the adverse outcomes (see 24 Supplementary data online, *Figure S8a-S8b*), we found that the ensemble model 25 combining the 10 DMPs, sex, age, fibrinogen, HDLC, and LVEF achieved an AUC of

1 0.83 (*Figure 3b*). When applying the models to the validation cohort (n=528), which 2 was assembled from three medical centers and independent of the discovery cohort in 3 which the models were built, we observed about 11% drop in both sensitivity and 4 specificity. Still, the ensemble model could well stratify CAD patients of different 5 risks of death in five years (P < 0.0001 (see *Figure 3c-3d* and Supplementary data 6 online, *Table S9*).

Similarly, the CG prognostic model for MACE performed the best when combining the 8 CpG sites with sex, age, fibrinogen, HDLC, and LVEF (AUC = 0.77) (*Figure 3e-3f*) and achieved a good patient stratification of five-year risk in the validation cohort (see *Figure 3g-3h* and Supplementary data online, *Table S10*).

11 Age is known as a strong risk factor for CVD. Observing the chronological 12 age predicted closely to the CG models, we explored the performance of several DNA methylation clocks, including GrimAge<sup>51</sup>, PhenoAge<sup>52</sup>, Hannum Clock<sup>53</sup>, and 13 Horvath Clock <sup>54</sup>. DNA methylation clocks have been shown to better represent one's 14 15 aging status. Indeed, most clock models achieved better prediction than the 16 chronological age models for death and MACE (see Supplementary data online, 17 *Figure S8c-S8d*) and performed equally well or even better than the CG prognostic 18 models. As these clocks comprised dozens to hundreds of CpG sites, one to two 19 orders of magnitude more than the maximal 10 CpG sites in our models, our CG 20 prognostic models are more succinct and specific.

21 Note that among our CAD patients with adverse outcomes, a vast majority had 22 the events occurred within the first 5 years of the ascertained period, therefore our 23 models mostly captured the risk of adversity in a relative near term.

#### 1 Contribution of genetic regulation to CAD prognosis

2 Methylation can be regulated genetically by quantitative trait loci (meQTL), thus 3 providing a tool for investigating how genetics influences CAD prognosis. We 4 queried the 115 DMPs against a meQTL dataset derived from 3,523 East Asians 5 (Methods). Compared with all CpG sites on the Infinium methylationEPIC beadchip, 6 the DMPs were enriched for both *cis*-meQTL, defined as within 1 Mb flanking regions (Hypergeometric P = 2.12E-08), and *trans*-meQTL, defined as >5 Mb or 7 8 SNP-CpG pair located on different chromosomes (Hypergeometric P = 3.55E-26). 9 Briefly, 70 DMPs were subjected to the regulation of 14,374 unique *cis*-meQTLs and 10 52 DMPs to 1,612 unique trans-meQTLs, with weak associations in most cases. 11 Compared with *trans*, DMPs in *cis* relations tended to have more meQTLs. 12 Altogether 92 of the 115 DMPs (80%) were regulated genetically (*Figure 4a-4d*).

13 We next assessed how these meQTLs performed in genetic association tests. 14 We genotyped 1,551 CAD patients using Illumina GSA array, who were recruited 15 from the three medical centers in China and partially overlap with our methylation 16 cohort. We derived 3,448,646 high-quality single nucleotide variants (SNVs) after 17 imputation and quality control, and performed genome-wide association studies 18 (GWAS) with death or MACE via logistic regression (Methods). Among the 14,374 19 cis-meQTLs paired with the DMPs, 8,362 were genotyped and therein fewer than 5% 20 SNPs displayed nominal association (P < 0.05) (see Supplementary data online, 21 *Figure S9a-S9b*). Such weak associations would be missed by GWAS, whereas our 22 EWAS analysis recovered them. The fact that 10s to 1000s of meQTLs regulating one 23 single DMP, each with a weak strength, suggested that the trickling of little genetic 24 signals had mounted to significant epigenetic outcomes, which resembled the 25 polygenic model in complex traits. As such, the most important DMPs could be

regulated by many meQTLs. Indeed, we observed that the DMP having most cismeQTLs was cg20015729, with a remarkable 1,842 *cis*-meQTLs spanning 678.84 Kb, and closest to the gene Ubiquitin conjugating enzyme E2 E2 (*UBE2E2*). Similarly, cg16500036 was associated with over 1,000 cis-meQTLs, and closest to the gene Activator of transcription and developmental regulator (*AUTS2*). DMPs having most trans-meQTLs were cg25563198 and cg25114611, both closest to the gene FKBP Prolyl Isomerase 5 (*FKBP5*) (*Figure 4e-4f*)

8 Pleiotropy at the nucleotide level was frequently observed in genetic studies <sup>55</sup>. 9 We were interested in learning the SNVs that simultaneously regulated DMP 10 methylation and gene expression, i.e., SNV with a dual role of meQTL and eQTL. 11 Therefore, we leveraged the pleiotropic association model in SMR (Methods) to 12 integrate meQTLs from Peng et al and eQTLs from eQTLGen. Briefly, 6,796 cis-13 meQTLs connected to 56 DMPs were identified as or closely located to eQTLs (P 14 <1.0E-6), which regulated the expression of 242 genes. To further distinguish 15 pleiotropy from linkage, we performed a HEIDI test against the null hypothesis that 16 the SMR association was due to pleiotropy. As such, we revealed that 1,785 cis-17 meQTLs were indeed eQTLs ( $P_{\text{HEIDI}} > 0.05$ ), ruling out the possibility that the 18 pleiotropic associations were caused by genotypes in linkage disequilibrium (LD). 19 These pleiotropic meQTLs/eQTLs were linked to 29 DMPs and 71 genes, forming 80 20 CpG-gene pairs (see Supplementary data online, *Table S11*).

It is worth noting the SNV rs10235487 (see Supplementary data online, *Figure S9c*). As a *cis*-meQTL, it regulated cg16500036, a common feature in the CG prognostic models of death and MACE. This CpG site was located on an enhancer predicted by the ABC model to interact with *AUTS2*, therefore its increased methylation level would theoretically decrease the expression of *AUTS2*. Meanwhile, as an eQTL, this SNV negatively correlated with the expression of *AUTS2* ( $P_{SMR}$  = 4.50E-09,  $P_{HEIDI} > 0.05$ ). Collectively, these pieces of evidence pointed to a strong connection of SNV rs10235487 to increased methylation of cg16500036 on an enhancer of *AUTS2*, which subsequently results in decreased expression of *AUTS2*, leading to poor CAD outcomes.

#### 6 **Prognostic genes in acute MI and stroke**

7 Our convergent findings presented above indicated that changes of methylation 8 perturbed expression of the key genes involved in regulating CAD progression (see 9 Supplementary data online, *Table S5*). To further investigate their effects, we 10 examined expression of the 100 prognostic genes in patients of MI or stroke, two 11 major adverse outcomes of CAD.

12 Bulk RNA sequencing of peripheral blood between MI patients and controls 13 were obtained. In addition, a recent study reported single-nuclei profiling of gene 14 expression and chromatin accessibility with spatial and time resolution, in which three 15 zones of the MI lesion tissues were interrogated. We reanalyzed these two datasets 16 and found that our prognostic genes displayed relatively small expression changes in 17 MI, whether in tissue or blood, as most expression changes were within 30% (Fig. 5a-18 5b). This likely reflects the nature of these genes being more sentinel rather than 19 violent players during the actual occurrence of the adverse events. A closer look 20 showed that 27 of the 100 prognostic genes changed their expression by 30% or more 21 in the 3 physiological zones: *myogenic*, representing non-ischemic or normal tissues; 22 ischemic, the lesion site; and *fibrotic*, representing lesion sites with advanced disease 23 progression (see Supplementary data online, Figure S10a and Supplementary data 24 online, Table S12).

1 We also examined expression of the prognostic genes in different cell types 2 (Figure 5c and Supplementary data online, Figure S10b). Notably, FKBP5, the gene 3 closest to the DMPs cg03546163 (a common marker in CG prognostic models for 4 death and MACE), cg25114611 and cg25563198 (having the largest number of trans-5 meQTL and ABC target genes), elevated its expression in MI by four folds in nearly 6 all cell types, and its expression levels were ever higher along the disease progression. 7 Conversely, AUTS2 nearest to cg16500036 (a common marker in the CG prognostic 8 models for death and MACE, and serving a dual role as meQTL and eQTL), 9 decreased its expression by 52% and 26% in immature innate lymphoid cells and 10 smooth muscle myoblast cell in MI, and decreased gradually in immature innate 11 lymphoid cells along the disease progression. **UBE2E2** nearest to cg20015729 (a 12 marker in the CG prognostic model for death), displayed highest expression in 13 adipocytes of the epicardial fat from the left ventricle; furthermore, we observed its 14 expression was decreased by 20% in immature innate lymphoid cells and native cells 15 of MI, and along the disease progression, it first decreased then elevated in several 16 cell types, including fibroblasts of the cardiac tissue, immature innate lymphoid, and 17 native cells, suggesting this gene may participate in cardiac repair after acute 18 myocardial injury.

As for stroke, in a dataset where gene expression in the peripheral blood from patients of acute ischemic stroke was studied, we found 14 prognostic genes displaying differential expression as compared to the healthy controls (Q < 0.05) (*Figure 5d*). Therein, *FKBP5* was among those having the greatest expression changes.

24

1 Therefore, there appears to be coherent evidence for the strongest signals, such 2 as those linked to FKBP5, AUTS2, and UBE2E2. We summarized them and 3 constructed the DMP – gene regulation models (*Figure 5e*).

# 4 **Discussion**

5 In this study, we presented comprehensive EWAS on more than 733,000 DNA 6 methylation sites distributed genome-wide against the survival time of adverse 7 outcomes in 933 CAD patients. We identified 115 CpG sites whose methylation 8 patterns were characteristic of patients with future adverse events. From a spectrum of 9 analyses on these DMPs, we obtained three main observations.

10 First, we learned that 72% of the DMPs were located on enhancers and 11 associated with genes involved in stress response, senescence, inflammation, and 12 vessel tube regulation. An additional investigation leveraging clinical measurements 13 revealed finer sub-categories, from which strong associations of the DMPs were 14 observed with: (1) three inflammation indices, namely fibrinogen, SII, and PLR, all 15 connected to platelets; (2) heart functions, namely LVEF and LVMI; and (3) HDLC. 16 As platelets and cholesterol were essential components of thrombosis, our results 17 suggested that early thrombo-inflammation and heart contraction functions mediated 18 the adverse outcomes in CAD. Indeed, prognostic models based on fibrinogen, LVEF, 19 or LVMI, each achieved AUC 0.65 or above. Interestingly, HDL is known in reverse 20 cholesterol transport, interacts with platelets and exerts an antithrombotic function by 21 suppressing the coagulation cascade and stimulation of clot fibrinolysis <sup>56</sup>. In our 22 analyses, DMPs were associated strongly with HDLC but little with other lipid 23 categories; furthermore, HDLC displayed stronger power than other lipid categories 24 in predicting adverse outcomes. As such, our study suggested that the ability to

remove cholesterol, rather than its accumulation, was more relevant to the adverse
 outcomes. A recent study discovered that LDLC, compared to the inflammation index
 C-reactive protein, was less effective in predicting future cardiovascular events and
 death <sup>57</sup>. Our study suggests that HDLC, not LDLC, may be a more relevant predictor.
 Therefore, our methylation study of CAD adverse outcomes may inspire new research
 for clinical translation.

7 Second, we observed a significant genetic component in the regulation of 8 CAD adverse outcomes. Strikingly, 80% of the DMPs could be mapped to known 9 meQTLs. In addition, important prognostic genes, which repetitively appeared as 10 most significant in various analyses, own the largest number of meQTLs for their 11 DMPs. For example, UBE2E2 and AUTS2, each had a DMP (cg20015729 and 12 cg16500036) associated with more than 1,000 cis-meQTLs. FKBP5 had two DMPs, 13 with one (cg25563198) associated with 267 cis-meQTLs and 273 trans-meQTLs, and 14 the other (cg25114611) associated with 270 *trans*-meQTLs. Interestingly, our analysis 15 showed that each of these meQTLs conferred a very weak GWAS signal; however, 16 when combined, they collectively regulated the important DMPs. Indeed, the most 17 important DMPs were regulated under significantly more meQTLs. Such genetic 18 regulation of DNA methylation resembles the polygenic model in GWAS studies of many complex traits <sup>58</sup>. Furthermore, we discovered that pleiotropic effects were 19 20 general. In total, 55% of the meQTLs (n=6,796) that regulated the adverse outcome 21 DMPs were in LD with known eQTLs. In fact, 15% cis-meQTLs (n=1,785) were 22 themselves eQTLs, as assessed by the SMR and HEIDI tests. These observations 23 suggested that a coupled genetic regulation of methylation and gene expression could 24 be a robust mechanism.

1 Third, most prognostic genes displayed subtle changes during the actual 2 adverse outcomes. This can be attributed to the nature of our study, that the 3 biomarkers we searched mainly served as early alarms. These biomarkers represented 4 proceeding events months to years before the adverse outcomes actually occurred. 5 That said, however, several prognostic genes did display drastic expression changes 6 during the adverse events and occurred repetitively as the most significant findings 7 along various analyses. These genes include FKBP5, AUTS2 and UBE2E2. FKBP5 is 8 an immunophilin protein that binds to immunosuppressive drugs. In our analysis, 9 FKBP5 had numerous DMPs associated with inflammation markers and heart functions. One of them, cg25114611, has been reported in acute MI<sup>59</sup>, death risk<sup>45</sup>, 10 inflammatory bowel disease <sup>60</sup>, Crohn's disease <sup>61</sup>, maternal BMI <sup>62</sup> and diabetes 11 mellitus<sup>63</sup>. FKBP5 expression was reported to be significantly altered in dilated 12 13 cardiomyopathy after heart transplantation and suggested to serve as a prognostic marker <sup>64</sup>. In our analysis of MI and stroke, *FKBP5* appeared as a most highly 14 15 regulated gene and involved in pathways of cellular senescence. Its elevation in MI 16 tissue was most drastic in innate immune lymphoid cells and adipocytes of the 17 epicardial fat of the left ventricle. These results align with the recent finding that 18 DNA demethylation led to increased expression of *FKBP5*, which in turn promoted 19 NF-kB signaling in immune cells, resulting in a proinflammatory response and increased cardiovascular risk <sup>65</sup>. Genetic variation in AUTS2 was reported in blood 20 pressure <sup>66</sup>, body mass index <sup>66</sup>, type 2 diabetes <sup>67</sup>, and mild heart defects <sup>68</sup>. UBE2E2 21 was associated with type 2 diabetes <sup>69</sup>, RR interval in electrocardiogram <sup>70</sup>, and fat 22 23 distribution <sup>71</sup>. Functional analysis indicated that loss of function of UBE2E2 in mouse primary adipose progenitor cells impaired adipocyte differentiation <sup>71</sup>. Such 24

1 ample connections to cardiometabolic diseases strongly support the notion that these

2 prognostic genes played critical roles in the CAD progression.

3 Leveraging the DNA methylation markers and the biological insights from our 4 analyses, we constructed succinct prognostic models for predicting death and MACE 5 in CAD patients. To facilitate clinical application, we purposefully selected 6 maximally 10 CpG sites; furthermore, we incorporated simple demographic 7 information such as chronological age and sex, and a few clinical features that were 8 relatively easy to obtain, including fibrinogen, LVEF, and HDLC. Our ensemble 9 models achieved AUC of 0.83 for predicting death and 0.77 for predicting MACE. 10 Furthermore, they achieved robust performance in CAD patients independently 11 assembled from three medical centers, proving their potential for clinical translation.

12 There are several limitations in our study. First, most of the adverse events 13 occurred to our CAD patients were within the first 5 years of ascertainment, therefore 14 our study captured short-term to intermediate signals. Given a longer interrogation 15 timespan, or a study with adverse events occurred in a longer time span, the DMPs 16 predicting longer-term adverse events could appear. Second, the number of patients 17 experienced adverse outcomes in the validation cohort was relatively small, i.e., there 18 are 248 in the discovery cohort and only 41 in the validation cohort. This limited the 19 power of replication. Indeed, 70-80% DMPs from the discovery cohort could not be 20 replicated in the validation cohort, and therefore removed from the bioinformatic 21 analysis and model construction. Third, although 850K EPIC array could assess CpG 22 methylation genome-wide, many CpG sites were not probed and therefore leaves a 23 large room for future discovery of prognostic markers.

1 To conclude, our study displays the value of leveraging DNA methylation of 2 peripheral blood in predicting future adverse events in CAD patients. Further studies 3 are warranted to investigate the roles of the methylation sites, genes, pathways, and 4 mediating phenotypes implicated in our study for a mechanistic understanding of the 5 CAD adverse outcomes.

#### 6 Acknowledgements

7 We thank the CAD patients for their willingness to consent and participate in this 8 scientific study. We thank medical staffs of the Guangdong Provincial People's 9 Hospital, particularly the nurses, for their diligent and careful follow-up of the 10 patients. We thank Dr. Sijia Wang for providing early access to the methylation QTL 11 datasets for our research. We also thank members of the Guangdong Provincial Key 12 Laboratory of Coronary Heart Disease Prevention and members of the Laboratory of 13 Intelligent Computing in Biomedicine in the Greater Bay Area Institute of Precision 14 Medicine (Guangzhou) for insightful discussions and suggestions.

## 15 **Funding**

This study was supported by the National Natural Science Foundation of China (No.
82274016, 32270626, 81872934), the Key-Area Research and Development Program
of Guangdong Province, China (No. 2019B020229003), Greater Bay Area Research
Institute of Precision Medicine (Guangzhou) Research Grants (I0005, R2001),
National key research and development program (No. 2017YFC0909301) and the
Science and Technology Program of Guangzhou (No. 2023B03J1251).

### 22 **Conflict of interest**

23 All authors declare no competing interests.

## 1 Data availability

2	Gene regulatory elements were obtained from ENCODE5 catalog
3	(https://www.encodeproject.org/). Enhancer-gene predictions by the ABC models in
4	131 biosamples were obtained from the ENGREITZ LAB
5	(https://www.engreitzlab.org/abc/). CpG sites associated with diseases and traits were
6	download from EWAS Catalog (http://www.ewascatalog.org/) and EWAS Atlas
7	(https://ngdc.cncb.ac.cn/ewas/atlas). meQTL summary statistic data were obtained
8	from Pan-mQTL (https://www.biosino.org/panmqtl/home). eQTL summary statistics
9	were derived from eQTLGen (https://www.eqtlgen.org/cis-eqtls.html). Single-nuclei
10	RNA sequencing data of MI patients were available from Zenodo data archive
11	(https://zenodo.org/record/6578047). Blood derived bulk RNA sequencing data were
12	obtained from GEO database (GSE61144 and GSE16561). Calculation of DNA
13	methylation age of GrimAge, Hannum clock, Hovath clock, and PhenoAge were
14	performed by DNA Methylation Age Calculator
15	(https://dnamage.genetics.ucla.edu/home).

## 16 Author Contributions

17 SZ and CP designed the study. SZ supervised and coordinated the overall study and 18 CP supervised the data analysis. SZ, XF, BZ, XC and CL assembled the study cohort. 19 MQ, QW, XT, QZ, XW, XC and CL consented the patients and supervised the patient 20 follow-up. MQ, QW, XT and HL collected samples and prepared them for DNA 21 methylation array. MQ and CP performed bioinformatic and statistical analyses and 22 generated the figures and tables. CP and MQ drafted the manuscript. All authors 23 contributed to result interpretation and discussions. CP, MQ and SZ critically 24 reviewed the manuscript.

## 1 Ethical approval

- 2 This study was approved by the Medical Research Ethics Committee of Guangdong
- 3 Provincial People's Hospital (approval number: GDREC2017071H) and complied
- 4 with the Declaration of Helsinki. All patients provided written informed consents.

# 5 **References**

Li S, Liu Z, Joseph P, Hu B, Yin L, Tse LA, *et al.* Modifiable risk factors
associated with cardiovascular disease and mortality in China: a PURE substudy. *Eur Heart J* 2022;43:2852-2863. doi: 10.1093/eurheartj/ehac268

9 2. Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, *et al.* Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. *Circulation* 2023;147:e93-e621. doi: 10.1161/CIR.00000000001123

3. Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, *et al.* Mortality, morbidity,
and risk factors in China and its provinces, 1990-2017: a systematic analysis for the
Global Burden of Disease Study 2017. *Lancet* 2019;**394**:1145-1158. doi:
10.1016/S0140-6736(19)30427-1

Cole JH, Miller JI, 3rd, Sperling LS, Weintraub WS. Long-term follow-up of
coronary artery disease presenting in young adults. *J Am Coll Cardiol* 2003;41:521528. doi: 10.1016/s0735-1097(02)02862-0

Proudfit WJ, Bruschke AV, MacMillan JP, Williams GW, Sones FM, Jr.
 Fifteen year survival study of patients with obstructive coronary artery disease.
 *Circulation* 1983;68:986-997. doi: 10.1161/01.cir.68.5.986

Brown JC, Gerhardt TE, Kwon E. Risk Factors For Coronary Artery Disease.
In. StatPearls. Treasure Island (FL); 2023.

Ananth CV, Rutherford C, Rosenfeld EB, Brandt JS, Graham H, Kostis WJ, *et al.* Epidemiologic trends and risk factors associated with the decline in mortality from coronary heart disease in the United States, 1990-2019. *Am Heart J* 2023;263:46-55. doi: 10.1016/j.ahj.2023.05.006

B. Drobni ZD, Kolossvary M, Karady J, Jermendy AL, Tarnoki AD, Tarnoki DL,
 *et al.* Heritability of Coronary Artery Disease: Insights From a Classical Twin Study.
 *Circ Cardiovasc Imaging* 2022;15:e013348. doi: 10.1161/CIRCIMAGING.121.013348

33 9. Zdravkovic S, Wienke A, Pedersen NL, Marenberg ME, Yashin AI, De Faire 34 U. Heritability of death from coronary heart disease: a 36-year follow-up of 20 966 35 Swedish twins. JIntern Med 2002;252:247-254. doi: 10.1046/j.1365-36 2796.2002.01029.x

Agha G, Mendelson MM, Ward-Caviness CK, Joehanes R, Huan T, Gondalia
R, *et al.* Blood Leukocyte DNA Methylation Predicts Risk of Future Myocardial
Infarction and Coronary Heart Disease. *Circulation* 2019;**140**:645-657. doi:
10.1161/CIRCULATIONAHA.118.039357

41 11. Navas-Acien A, Domingo-Relloso A, Subedi P, Riffo-Campos AL, Xia R,
42 Gomez L, *et al.* Blood DNA Methylation and Incident Coronary Heart Disease:

1 Evidence From the Strong Heart Study. JAMA Cardiol 2021;6:1237-1246. doi: 2 10.1001/jamacardio.2021.2704

3 12. Zhang W, Song M, Qu J, Liu GH. Epigenetic Modifications in Cardiovascular

4 Aging and Diseases. Circ Res 2018;**123**:773-786. doi: 5

- 10.1161/CIRCRESAHA.118.312497
- Joehanes R, Just AC, Marioni RE, Pilling LC, Reynolds LM, Mandaviya PR, 6 13.
- 7 et al. Epigenetic Signatures of Cigarette Smoking. Circ Cardiovasc Genet 8 2016;**9**:436-447. doi: 10.1161/CIRCGENETICS.116.001506
- 9 14. Dekkers KF, van Iterson M, Slieker RC, Moed MH, Bonder MJ, van Galen M,
- 10 et al. Blood lipids influence DNA methylation in circulating cells. Genome Biol 11 2016;**17**:138. doi: 10.1186/s13059-016-1000-6
- 12 Ligthart S, Marzi C, Aslibekyan S, Mendelson MM, Conneely KN, Tanaka T, 15. 13 et al. DNA methylation signatures of chronic low-grade inflammation are associated 14 with complex diseases. Genome Biol 2016;17:255. doi: 10.1186/s13059-016-1119-5
- 15 Richard MA, Huan T, Ligthart S, Gondalia R, Jhun MA, Brody JA, et al. 16.
- 16 DNA Methylation Analysis Identifies Loci for Blood Pressure Regulation. Am J Hum 17 Genet 2017;101:888-902. doi: 10.1016/j.ajhg.2017.09.028
- 18 17. Wahl S, Drong A, Lehne B, Loh M, Scott WR, Kunze S, et al. Epigenome-
- 19 wide association study of body mass index, and the adverse outcomes of adiposity. 20 Nature 2017;541:81-86. doi: 10.1038/nature20784
- 21 18. Abdulrahim JW, Kwee LC, Grass E, Siegler IC, Williams R, Karra R, et al. 22 Epigenome-Wide Association Study for All-Cause Mortality in a Cardiovascular 23 Cohort Identifies Differential Methylation in Castor Zinc Finger 1 (CASZ1). J Am 24 Heart Assoc 2019;8:e013228. doi: 10.1161/JAHA.119.013228
- 25 19. Zhang Y, Wilson R, Heiss J, Breitling LP, Saum KU, Schottker B, et al. DNA 26 methylation signatures in peripheral blood strongly predict all-cause mortality. Nat 27 Commun 2017;8:14617. doi: 10.1038/ncomms14617
- 28 20. Wang Z, Zhu Q, Liu Y, Chen S, Zhang Y, Ma Q, et al. Genome-wide 29 association study of metabolites in patients with coronary artery disease identified 30 novel metabolite quantitative trait loci. Clin Transl Med 2021;11:e290. doi: 31 10.1002/ctm2.290
- 32 Morris TJ, Butcher LM, Feber A, Teschendorff AE, Chakravarthy AR, 21. 33 Wojdacz TK, et al. ChAMP: 450k Chip Analysis Methylation Pipeline. 34 Bioinformatics 2014;30:428-430. doi: 10.1093/bioinformatics/btt684
- 35 22. Tian Y, Morris TJ, Webster AP, Yang Z, Beck S, Feber A, et al. ChAMP: 36 updated methylation analysis pipeline for Illumina BeadChips. Bioinformatics 37 2017;**33**:3982-3984. doi: 10.1093/bioinformatics/btx513
- 38 23. Nordlund J, Backlin CL, Wahlberg P, Busche S, Berglund EC, Eloranta ML, 39 et al. Genome-wide signatures of differential DNA methylation in pediatric acute 40 lymphoblastic leukemia. Genome Biol 2013;14:r105. doi: 10.1186/gb-2013-14-9-r105
- 41 24. Teschendorff AE, Marabita F, Lechner M, Bartlett T, Tegner J, Gomez-
- 42 Cabrero D, et al. A beta-mixture quantile normalization method for correcting probe 43 design bias in Illumina Infinium 450 k DNA methylation data. *Bioinformatics* 44 2013;29:189-196. doi: 10.1093/bioinformatics/bts680
- 45 Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ, 25. 46 Nelson HH, et al. DNA methylation arrays as surrogate measures of cell mixture 47 distribution. BMC Bioinformatics 2012;13:86. doi: 10.1186/1471-2105-13-86
- 48 Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic 26.
- 49 variants from high-throughput sequencing data. Nucleic Acids Res 2010;38:e164. doi:
- 50 10.1093/nar/gkq603

1 27. Consortium EP, Moore JE, Purcaro MJ, Pratt HE, Epstein CB, Shoresh N, et 2 al. Expanded encyclopaedias of DNA elements in the human and mouse genomes. 3 Nature 2020;583:699-710. doi: 10.1038/s41586-020-2493-4 Bernstein BE, Stamatoyannopoulos JA, Costello JF, Ren B, Milosavljevic A, 4 28. 5 Meissner A, et al. The NIH Roadmap Epigenomics Mapping Consortium. Nat 6 *Biotechnol* 2010;**28**:1045-1048. doi: 10.1038/nbt1010-1045 Roadmap Epigenomics C, Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen 7 29. 8 A, et al. Integrative analysis of 111 reference human epigenomes. Nature 9 2015;**518**:317-330. doi: 10.1038/nature14248 10 30. Nasser J, Bergman DT, Fulco CP, Guckelberger P, Doughty BR, Patwardhan 11 TA, et al. Genome-wide enhancer maps link risk variants to disease genes. Nature 12 2021;**593**:238-243. doi: 10.1038/s41586-021-03446-x 13 Fulco CP, Nasser J, Jones TR, Munson G, Bergman DT, Subramanian V, et al. 31. 14 Activity-by-contact model of enhancer-promoter regulation from thousands of 15 CRISPR perturbations. Nat Genet 2019;51:1664-1669. doi: 10.1038/s41588-019-16 0538-0 17 32. Boix CA, James BT, Park YP, Meuleman W, Kellis M. Regulatory genomic 18 circuitry of human disease loci by integrative epigenomics. *Nature* 2021;**590**:300-307. 19 doi: 10.1038/s41586-020-03145-z 20 Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powell JE, et al. Integration 33. 21 of summary data from GWAS and eQTL studies predicts complex trait gene targets. 22 Nat Genet 2016;48:481-487. doi: 10.1038/ng.3538 23 Peng Q, Liu X, Li W, Jing H, Li J, Gao X, et al. Analysis of blood 34. 24 methylation quantitative trait loci in East Asians identifies ancestry-specific effects 25 associated with complex trait variation. Nat Genet 2023. doi: 26 35. Genomes Project C, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang 27 HM, et al. A global reference for human genetic variation. Nature 2015;526:68-74. 28 doi: 10.1038/nature15393 29 36. Kuppe C, Ramirez Flores RO, Li Z, Hayat S, Levinson RT, Liao X, et al. 30 Spatial multi-omic map of human myocardial infarction. Nature 2022;608:766-777. 31 doi: 10.1038/s41586-022-05060-x 32 37. Hao Y, Hao S, Andersen-Nissen E, Mauck WM, 3rd, Zheng S, Butler A, et al. 33 Integrated analysis of multimodal single-cell data. Cell 2021;184:3573-3587 e3529. 34 doi: 10.1016/j.cell.2021.04.048 35 38. Park HJ, Noh JH, Eun JW, Koh YS, Seo SM, Park WS, et al. Assessment and 36 diagnostic relevance of novel serum biomarkers for early decision of ST-elevation 37 myocardial infarction. *Oncotarget* 2015;**6**:12970-12983. doi: 38 10.18632/oncotarget.4001 39 Barr TL, Conley Y, Ding J, Dillman A, Warach S, Singleton A, et al. 39. 40 Genomic biomarkers and cellular pathways of ischemic stroke by RNA gene 41 expression profiling. Neurology 2010;75:1009-1014. doi: 42 10.1212/WNL.0b013e3181f2b37f 43 40. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers 44 differential expression analyses for RNA-sequencing and microarray studies. Nucleic 45 Acids Res 2015;43:e47. doi: 10.1093/nar/gkv007 Battram T, Yousefi P, Crawford G, Prince C, Sheikhali Babaei M, Sharp G, et 46 41. 47 al. The EWAS Catalog: a database of epigenome-wide association studies. Wellcome 48 Open Res 2022;7:41. doi: 10.12688/wellcomeopenres.17598.2 49 42. Li M, Zou D, Li Z, Gao R, Sang J, Zhang Y, et al. EWAS Atlas: a curated 50 knowledgebase of epigenome-wide association studies. Nucleic Acids Res

1 2019;**47**:D983-D988. doi: 10.1093/nar/gky1027

2 43. Demerath EW, Guan W, Grove ML, Aslibekyan S, Mendelson M, Zhou YH,

3 et al. Epigenome-wide association study (EWAS) of BMI, BMI change and waist

4 circumference in African American adults identifies multiple replicated loci. Hum

5 *Mol Genet* 2015;**24**:4464-4479. doi: 10.1093/hmg/ddv161

44. Yamada Y, Horibe H, Oguri M, Sakuma J, Takeuchi I, Yasukochi Y, *et al.*Identification of novel hyper- or hypomethylated CpG sites and genes associated with
atherosclerotic plaque using an epigenome-wide association study. *Int J Mol Med*

9 2018;**41**:2724-2732. doi: 10.3892/ijmm.2018.3453

45. Colicino E, Marioni R, Ward-Caviness C, Gondalia R, Guan W, Chen B, *et al.*Blood DNA methylation sites predict death risk in a longitudinal study of 12, 300

12 individuals. *Aging (Albany NY)* 2020;**12**:14092-14124. doi: 10.18632/aging.103408

46. Oliva M, Demanelis K, Lu Y, Chernoff M, Jasmine F, Ahsan H, *et al.* DNA
methylation QTL mapping across diverse human tissues provides molecular links
between genetic variation and complex traits. *Nat Genet* 2023;55:112-122. doi:
10.1038/s41588-022-01248-z

47. Wang Y, Song C, Zhao J, Zhang Y, Zhao X, Feng C, *et al.* SEdb 2.0: a
comprehensive super-enhancer database of human and mouse. *Nucleic Acids Res*2023;51:D280-D290. doi: 10.1093/nar/gkac968

48. Yang YL, Wu CH, Hsu PF, Chen SC, Huang SS, Chan WL, *et al.* Systemic
immune-inflammation index (SII) predicted clinical outcome in patients with
coronary artery disease. *Eur J Clin Invest* 2020;**50**:e13230. doi: 10.1111/eci.13230

49. Hahn J, Bressler J, Domingo-Relloso A, Chen MH, McCartney DL, Teumer A, *et al.* DNA methylation analysis is used to identify novel genetic loci associated with
circulating fibrinogen levels in blood. *J Thromb Haemost* 2023. doi:
10.1016/j.jtha.2023.01.015

50. Balta S, Ozturk C. The platelet-lymphocyte ratio: A simple, inexpensive and
rapid prognostic marker for cardiovascular events. *Platelets* 2015;26:680-681. doi:
10.3109/09537104.2014.979340

Lu AT, Quach A, Wilson JG, Reiner AP, Aviv A, Raj K, *et al.* DNA
methylation GrimAge strongly predicts lifespan and healthspan. *Aging (Albany NY)*2019;**11**:303-327. doi: 10.18632/aging.101684

52. Levine ME, Lu AT, Quach A, Chen BH, Assimes TL, Bandinelli S, *et al.* An
epigenetic biomarker of aging for lifespan and healthspan. *Aging (Albany NY)*2018;10:573-591. doi: 10.18632/aging.101414

36 53. Hannum G, Guinney J, Zhao L, Zhang L, Hughes G, Sadda S, *et al.* Genome37 wide methylation profiles reveal quantitative views of human aging rates. *Mol Cell*38 2013;49:359-367. doi: 10.1016/j.molcel.2012.10.016

Horvath S. DNA methylation age of human tissues and cell types. *Genome Biol* 2013;14:R115. doi: 10.1186/gb-2013-14-10-r115

41 55. Geiler-Samerotte KA, Li S, Lazaris C, Taylor A, Ziv N, Ramjeawan C, *et al.*42 Extent and context dependence of pleiotropy revealed by high-throughput single-cell
43 phenotyping. *PLoS Biol* 2020;**18**:e3000836. doi: 10.1371/journal.pbio.3000836

44 56. van der Stoep M, Korporaal SJ, Van Eck M. High-density lipoprotein as a
45 modulator of platelet and coagulation responses. *Cardiovasc Res* 2014;**103**:362-371.
46 doi: 10.1093/cvr/cvu137

47 57. Ridker PM, Bhatt DL, Pradhan AD, Glynn RJ, MacFadyen JG, Nissen SE, *et al.* Inflammation and cholesterol as predictors of cardiovascular events among
49 patients receiving statin therapy: a collaborative analysis of three randomised trials.
50 *Lancet* 2023;401:1293-1301. doi: 10.1016/S0140-6736(23)00215-5

58. 1 Shi H, Kichaev G, Pasaniuc B. Contrasting the Genetic Architecture of 30 2 Complex Traits from Summary Association Data. Am J Hum Genet 2016;99:139-153. 3 doi: 10.1016/j.ajhg.2016.05.013 4 59. Fernandez-Sanles A, Sayols-Baixeras S, Subirana I, Senti M, Perez-Fernandez 5 S, de Castro Moura M, et al. DNA methylation biomarkers of myocardial infarction 6 and cardiovascular disease. Clin Epigenetics 2021;13:86. doi: 10.1186/s13148-021-7 01078-6 8 60. Ventham NT, Kennedy NA, Adams AT, Kalla R, Heath S, O'Leary KR, et al. 9 Integrative epigenome-wide analysis demonstrates that DNA methylation may 10 mediate genetic risk in inflammatory bowel disease. Nat Commun 2016;7:13507. doi: 11 10.1038/ncomms13507 12 61. Somineni HK, Venkateswaran S, Kilaru V, Marigorta UM, Mo A, Okou DT, 13 et al. Blood-Derived DNA Methylation Signatures of Crohn's Disease and Severity of 14 Intestinal Inflammation. *Gastroenterology* 2019:**156**:2254-2265 e2253. doi: 15 10.1053/j.gastro.2019.01.270 Sharp GC, Salas LA, Monnereau C, Allard C, Yousefi P, Everson TM, et al. 16 62. 17 Maternal BMI at the start of pregnancy and offspring epigenome-wide DNA 18 methylation: findings from the pregnancy and childhood epigenetics (PACE) 19 consortium. Hum Mol Genet 2017;26:4067-4085. doi: 10.1093/hmg/ddx290 20 Antoun E, Kitaba NT, Titcombe P, Dalrymple KV, Garratt ES, Barton SJ, et 63. 21 al. Maternal dysglycaemia, changes in the infant's epigenome modified with a diet 22 and physical activity intervention in pregnancy: Secondary analysis of a randomised 23 control trial. PLoS Med 2020;17:e1003229. doi: 10.1371/journal.pmed.1003229 24 Wei Y, Cao H, Peng YY, Zhang B. Alterated gene expression in dilated 64. 25 cardiomyopathy after left ventricular assist device support by bioinformatics analysis. 26 Front Cardiovasc Med 2023;10:1013057. doi: 10.3389/fcvm.2023.1013057 27 65. Zannas AS, Jia M, Hafner K, Baumert J, Wiechmann T, Pape JC, et al. 28 Epigenetic upregulation of FKBP5 by aging and stress contributes to NF-kappaB-29 driven inflammation and cardiovascular risk. Proc Natl Acad Sci U S A 30 2019;**116**:11370-11379. doi: 10.1073/pnas.1816847116 31 Sakaue S, Kanai M, Tanigawa Y, Karjalainen J, Kurki M, Koshiba S, et al. A 66. 32 cross-population atlas of genetic associations for 220 human phenotypes. Nat Genet 33 2021;53:1415-1424. doi: 10.1038/s41588-021-00931-x 34 Spracklen CN, Horikoshi M, Kim YJ, Lin K, Bragg F, Moon S, et al. 67. 35 Identification of type 2 diabetes loci in 433,540 East Asian individuals. Nature 36 2020;**582**:240-245. doi: 10.1038/s41586-020-2263-3 37 Beunders G, van de Kamp J, Vasudevan P, Morton J, Smets K, Kleefstra T, et 68. 38 al. A detailed clinical analysis of 13 patients with AUTS2 syndrome further delineates 39 the phenotypic spectrum and underscores the behavioural phenotype. J Med Genet 40 2016;**53**:523-532. doi: 10.1136/jmedgenet-2015-103601 41 Yamauchi T, Hara K, Maeda S, Yasuda K, Takahashi A, Horikoshi M, et al. A 69. 42 genome-wide association study in the Japanese population identifies susceptibility 43 loci for type 2 diabetes at UBE2E2 and C2CD4A-C2CD4B. Nat Genet 2010;42:864-44 868. doi: 10.1038/ng.660 45 Noordam R, Sitlani CM, Avery CL, Stewart JD, Gogarten SM, Wiggins KL, 70. et al. A genome-wide interaction analysis of tricyclic/tetracyclic antidepressants and 46 47 RR and QT intervals: a pharmacogenomics study from the Cohorts for Heart and 48 Aging Research in Genomic Epidemiology (CHARGE) consortium. J Med Genet 49 2017;**54**:313-323. doi: 10.1136/jmedgenet-2016-104112 50 Chu AY, Deng X, Fisher VA, Drong A, Zhang Y, Feitosa MF, et al. 71.

- 1 Multiethnic genome-wide meta-analysis of ectopic fat depots identifies loci associated
- 2 with adipocyte development and differentiation. Nat Genet 2017;49:125-130. doi:
- 3 10.1038/ng.3738
- 4

5

## 1 Figure Legends

2 Figure 1. Epigenome-wide association studies on DNA methylation and CAD 3 adverse outcomes. (a) Overall study design. Patients in the discovery cohort were 4 enrolled from one medical center, whereas patients in the validation cohort were 5 recruited from three medical centers in the China. Baseline characteristics were 6 collected during the enrollment. DNA methylation of peripheral blood leukocytes was 7 measured by Illumina MethylationEPIC BeadChip on ~ 850,0000 sites. Differentially 8 methylated sites associated with death or MACE were identified, prognostic risk 9 models were built, and biological mechanisms were inferred. This graph was created 10 via <u>https://www.biorender.com/</u>. (b) EWAS results of death and MACE based on the 11 discovery cohort were presented in Manhattan plot. Red dash line marks the 12 Bonferroni corrected P value threshold.

13 Figure 2. Epigenome-wide association studies of DNA methylation reveals 14 differentially methylated CpGs associated with CAD adverse outcomes. (a) 15 Genomic distribution of the 115 DMPs consistently associated with death and MACE 16 in both the discovery and the validation cohorts. Bars represent P values from the 17 discovery cohort. On the bottom of each circle, hypermethylated sites are marked in 18 purple and hypomethylated sites in green. (b) Pathway enrichment of the genes 19 connected to DMPs against the KEGG database. (c) Diseases or traits enriched among 20 the genes connected to DMPs against the GWASCatalog database. (d) Association of 21 the DMPs with three categories of clinical measurements: inflammation indices, lipids, 22 and heart functions. Measurements were recorded in both the discovery (upper) and 23 the validation (lower) cohort. WBC: whole plasma cell count, LMR: lymphocyte-24 monocyte ratio, NLR: neutrophil-lymphocyte ratio, PLR: platelet-lymphocyte ratio, 25 FIB: fibrinogen, SII: systemic immune-inflammation index, LDLC: low-density

lipoprotein cholesterol, HDLC: high-density lipoprotein cholesterol, CHOL: total
 cholesterol, TRIG: triglycerides, LVEF: left ventricular ejection fraction, LVMI: left
 ventricular mass index.

4 Figure 3. Prognostic models for CAD adverse outcomes. (a-b) ROC curves of the 5 prognostic models of death constructed from the discovery cohort. The CG model 6 consists of 10 CpG sites. The Ensemble model is composed of CG + Sex + Age + FIB7 + HDLC + LVEF. (c) Predicted risk of death in the validation cohort, by applying the 8 model of CG + Sex + Age. (d) Predicted risk of death in the validation cohort, by 9 applying the Ensemble model. (e-f) ROC curves of the prognostic models of MACE 10 constructed from the discovery cohort. Features are the same as those for the model of 11 death, except that the CG model consists of 8 CpG sites. (g) Predicted risk scores of MACE in the validation cohort, by applying the model of CG + Sex + Age. (h) 12 13 Predicted risk of MACE in the validation cohort, by applying the Ensemble model. 14 PLR: platelet-lymphocyte ratio, FIB: fibrinogen, SII: systemic immune-inflammation 15 index, HDLC: high-density lipoprotein cholesterol, LVEF: left ventricular ejection 16 fraction, LVMI: left ventricular mass index.

17 Figure 4. Genetic regulation of DMPs associated with CAD adverse outcomes. 18 meQTLs associated with the 115 DMPs are listed for (a) cis-meQTL and (b) trans-19 meQTL. For each DMP, the number of associated meQTLs was shown. (c) The bar 20 plots display the proportion of CpGs having meQTLs. (d) Association strength, beta, 21 between the DMPs and the meQTLs. EPIC: all CpGs in the Infinium 22 methylationEPIC Beadchip. DMP: 115 CpGs associated with CAD adverse outcomes. 23 (e) Genomic distribution of the 1,842 cis-meQTLs associated with cg20015729, 24 which was located on the UBE2E2 gene. (f) meQTLs for two DMPs located on the 25 promoter of the gene FKBP5: cg25563198 associated with 267 cis-meQTLs and 273

- 1 trans-meQTLs within chromosome 4; cg25114611 associated with 270 trans-meQTLs
- 2 within chromosome 4. Linkage disequilibrium between the meQTLs, as measured by
- 3 R^2, was indicated by the triangle plots.

## 4 Figure 5. Expression of the prognostic genes in myocardial infarction (MI) and

5 stroke. Differential gene expression in the MI patients compared to healthy controls 6 in (a) MI lesion tissues and (b) peripheral blood. (c) Expression of the prognostic 7 genes FKBP5, AUTS2 and UBE2E2 in various cell types in three locations of the MI 8 tissues: myogenic (i.e., nonischemic zone), ischemic, and fibrotic (i.e., advanced MI 9 zone). (d) Differential gene expression in the peripheral blood of stroke patients 10 compared to the healthy controls. In all volcano plots of gene expression, prognostic 11 genes inferred from our DNA methylation study were labeled. (e) A collection of 12 evidence for the CpG sites associated with the prognostic genes FKBP5, AUTS2, and 13 UBE2E2.

14













В





